ClinicalTrials.gg
RecruitingNCT07053800LUMINAUpdated Oct 30, 2026

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

A Phase 2 interventional study of Obecabtagene autoleucel in Lupus Nephritis, sponsored by Autolus Limited. Recruiting at 16 sites in 5 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Autolus Limited · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 30, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Lupus Nephritis with a site in United Kingdom — 4 open to participants now, 8 under way, 2 of them phase 3. Lupus Nephritis · United Kingdom.

Planned enrollment
19th of 23
35 · median 100
Started
2026
the only one that year
Phase 2
13 of 24
2 open now
Registered
23rd of 24
by date
Lead sponsor
1 of 24
Autolus Limited

Among the 24 studies in Lupus Nephritis with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2026, is one of 13 in phase 2, and was the 23rd registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

4 of the 24 studies in Lupus Nephritis with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lupus Nephritis with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).

Read the detailed description

This is a Phase 2 study to determine the efficacy and safety of obe-cel in participants with severe, refractory SLE with active LN.

The study comprises 3 periods:

  1. Screening Period: From Day -30 (+7) to Day of Enrollment
  2. Treatment Period: From Day -8 to Day 1 - Participants will be evaluated to confirm eligibility for lymphodepletion, and thereafter receive lymphodepletion.

    Obe-cel Administration: If the participant's eligibility for receiving obe-cel infusion is confirmed, the participant is to receive a single obe-cel infusion on Day 1.

  3. Post-treatment Period: From Day 1 to End of Study all participants will be followed up for efficacy and safety evaluation.
03

Conditions studied

  • Lupus Nephritis

Keywords

  • Systemic lupus erythematosus
  • Refractory systemic lupus erythematosus
  • Lupus nephritis
  • Obecabtagene autoleucel
  • Obe-cel
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give written for participation in the study or written informed consent signed by a legal guardian or representative
  • Ability and willingness to adhere to protocol's Schedule of Activities and other requirements
  • Participants must be 12 to 65 years of age inclusive at the time of signing the informed consent.
  • Female Participants: - a female participant is eligible to participate if she is not pregnant or breastfeeding
  • Diagnosis of SLE fulfilling the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus.
  • Positive for at least 1 of the following autoantibodies: antinuclear antibodies (ANA), or anti-dsDNA or anti-Smith.
  • Severe, Active SLE defined as:

    • SLEDAI-2K score of ≥ 8 points AND
    • Severe active LN based on a renal : Class III, IV or V (V only in combination with class III or IV)
  • SLE defined as failure to

Exclusion criteria

Exclusion Criteria:

  • Prior treatment at any time with anti-CD19 therapy
  • More than 1 acute, severe lupus-related flare during screening that needs immediate treatment and/or makes the washout impossible
  • Significant, likely irreversible organ damage related to SLE (e.g., end-stage renal disease) that in the opinion of the Investigator renders CD19 CAR T cell therapy unlikely to benefit the participant
  • History of primary antiphospholipid antibody syndrome
  • Active or uncontrolled fungal, bacterial, or viral infection
  • History of malignant neoplasms unless disease free for at least 24 months
  • History of heart, lung, renal, liver transplant or hematopoietic stem cell transplant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Obe-cel

    Biological: Obecabtagene autoleucel

Interventions

  • Obecabtagene autoleucel (obe-cel) given as a single infusion

    Also known as: Obe-cel

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve complete renal response (CRR)

    CRR is a composite endpoint

    Time frame: Month 6

Secondary outcomes

  1. Proportion of participants achieving remission per Definition of Remission in SLE (DORIS) criteria

    DORIS is a composite endpoint

    Time frame: Month 6

  2. Proportion of participants achieving CRR over time

    CRR is a composite endpoint

    Time frame: Up to Month 24

  3. Time to CRR

    CRR is a composite endpoint

    Time frame: Up to Month 24

  4. Proportion of participants with Partial Renal Response (PRR)

    PRR is a composite endpoint

    Time frame: Up to Month 24

  5. Time to PRR

    PRR is a composite endpoint

    Time frame: Up to Month 24

  6. Proportion of participants achieving remission per DORIS criteria over time

    DORIS is a composite endpoint

    Time frame: Up to Month 24

  7. Time to achieving remission per DORIS criteria

    DORIS is a composite endpoint

    Time frame: Up to Month 24

  8. Time to renal flare

    Renal flare is a composite endpoint

    Time frame: Up to Month 24

  9. Proportion of participants achieving Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 0 over time

    SLEDAI-2K is a composite index of disease activity

    Time frame: Up to Month 24

  10. Proportion of participants achieving Lupus Low Disease Activity State (LLDAS) over time

    LLDAS is a composite endpoint

    Time frame: Up to Month 24

  11. Time to LLDAS

    LLDAS is a composite endpoint

    Time frame: Up to Month 24

  12. Time to first disease flare according to Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI-2K Flare Index (SFI) post-obe-cel infusion

    SFI is a composite index to identify disease flares

    Time frame: Up to Month 24

  13. To evaluate safety of obe-cel

    Proportion of participants with adverse events (AEs)

    Time frame: Up to Month 24

07

Study locations

16 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jul 8, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Oct 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Texas Children's Hospital · Houston, United States
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site added
    Show site
    • Texas Children's Hospital · Houston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07053800
Lead sponsor
Autolus Limited
Collaborators
PPD Development, LP
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Jan 16, 2026
Primary completion
Aug 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Autolus Ltd
Contact
clinicaltrials@autolus.com
+44 (0)203 911 4385

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obecabtagene autoleucel

Start the discussion